Rheumatoid arthritis

Comorbidities and chance of remission in patients with early rheumatoid arthritis receiving methotrexate as first-line therapy: a Swedish observational nationwide study

RMD OpenPublished Observational nationwide register-based cohort study

Authors' conclusion

Comorbidities decrease the chance of reaching remission on methotrexate as DMARD monotherapy in patients with early RA and are important to consider when assessing treatment outcomes.

Study context

Population
Patients diagnosed with early rheumatoid arthritis (RA) 2007–2020 in Sweden, receiving MTX monotherapy as first disease-modifying antirheumatic drug (DMARD)7,643 with 3-month Disease Activity Score (DAS28)
Participants
11,001 patients
Exposure
Patients with vs without each comorbidity category
  • Chronic kidney diseasen = 38
  • Previous cancern = 319
Outcome
Failure to reach DAS28 remission
Follow-up
3 months
Methodological detailsnationwide Swedish clinical and quality registers, modified Poisson regression, RR adjusted for sex and age
  • Nationwide Swedish clinical and quality registers
  • Modified Poisson regression
  • RR adjusted for sex and age

Main finding

As reported in the abstract

Not reaching DAS28 remission on MTX monotherapy, by comorbidity category
RR for not reaching DAS28 remission (adjusted for sex and age) (95% CI)
Endocrine comorbidity
1.08(1.01–1.15)
Gastrointestinal comorbidity
1.16(1.03–1.30)
Infectious comorbidity
1.21(1.06–1.38)
Psychiatric comorbidity
1.24(1.15–1.35)
Respiratory comorbidity
1.16(1.01–1.32)
≥3 comorbidity categories: higher risk of DAS28 remission failure at 3 months
27%

Observational data: associations, not effects.

Secondary outcomes

Secondary outcomes (Boolean, SDAI/CDAI remission, EULAR response, no swollen joints at 3 and 6 months)

A similar pattern was observed for the secondary outcomes

Original publication

Comorbidities and chance of remission in patients with early rheumatoid arthritis receiving methotrexate as first-line therapy: a Swedish observational nationwide study. RMD Open. Published 20 December 2023. doi:10.1136/rmdopen-2023-003714

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.